Answers are grounded in this paper and cite their sources.
Clinical evaluation shows SGLT2 inhibitors improve outcomes in Fabry disease patients, indicating potential benefits for certain individuals.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lenders et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: